These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7833464)

  • 1. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions.
    Heddle NM; Blajchman MA
    Blood; 1995 Feb; 85(3):603-6. PubMed ID: 7833464
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions.
    Vamvakas EC
    Transfus Med Rev; 1998 Oct; 12(4):258-70. PubMed ID: 9798269
    [No Abstract]   [Full Text] [Related]  

  • 3. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
    Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
    Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.
    van Marwijk Kooy M; van Prooijen HC; Moes M; Bosma-Stants I; Akkerman JW
    Blood; 1991 Jan; 77(1):201-5. PubMed ID: 1984797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management.
    Pavenski K; Freedman J; Semple JW
    Tissue Antigens; 2012 Apr; 79(4):237-45. PubMed ID: 22385314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of platelet transfusion refractoriness and HLA alloimmunization by leukocyte filtered platelet transfusion: a meta analysis].
    Yuan Q; Chen X; Cheng L; Zhou CH; Fu XM; Li YP; Wang NH; Wang L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Aug; 33(4):412-20. PubMed ID: 21906451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Refractory effect and alloimmunization after transfusion of thrombocytes].
    Volkova RI; Agranenko VA
    Gematol Transfuziol; 1992 Feb; 37(2):16-21. PubMed ID: 1426903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
    Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
    Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.
    Stanworth SJ; Navarrete C; Estcourt L; Marsh J
    Br J Haematol; 2015 Nov; 171(3):297-305. PubMed ID: 26194869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical aspects of platelet transfusions.
    Murphy MF; Waters AH
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):389-96. PubMed ID: 1893071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
    Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
    J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of pathogen-reduced platelet transfusions on HLA alloimmunization in hemato-oncological patients.
    Saris A; Kerkhoffs JL; Norris PJ; van Ham SM; Ten Brinke A; Brand A; van der Meer PF; Zwaginga JJ
    Transfusion; 2019 Feb; 59(2):470-481. PubMed ID: 30499599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of HLA alloimmunization: role of leukocyte depletion and UV-B irradiation.
    Snyder EL
    Yale J Biol Med; 1990; 63(5):419-27. PubMed ID: 2293501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.
    Seftel MD; Growe GH; Petraszko T; Benny WB; Le A; Lee CY; Spinelli JJ; Sutherland HJ; Tsang P; Hogge DE
    Blood; 2004 Jan; 103(1):333-9. PubMed ID: 12958065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
    Sniecinski I; O'Donnell MR; Nowicki B; Hill LR
    Blood; 1988 May; 71(5):1402-7. PubMed ID: 3282572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion.
    Blajchman MA; Bardossy L; Carmen RA; Goldman M; Heddle NM; Singal DP
    Blood; 1992 Mar; 79(5):1371-5. PubMed ID: 1536960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Transfusion of platelet concentrates].
    Rieux C; Lee K; Lavaud A; Bierling P
    Ann Med Interne (Paris); 1999 Dec; 150(8):631-41. PubMed ID: 10686645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects of platelet transfusion.
    Williamson LM
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):643-6. PubMed ID: 1333290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.